Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant

Inclusion criteria * Male or female recipients of a first bilateral or single lung or lobar allograft who are suitable to receive Neoral/ corticosteroids/ azathioprine/ and Basiliximab (Simulect). * Patients greater than 18 years of age. * Patients capable of understanding the purposes and risks of the study and who have given informed written consent. Exclusion Criteria: * Patients who require immunosuppressive therapy other than the study medications. * Patients participating in another (investigational) drug trial or who have participated in such a study within 30 days prior to transplantation. * Pregnant mothers, nursing women. * Women unwilling to use adequate contraception during and for 3 months after receiving study drug. * Patients receiving or requiring other investigational drugs, except antibiotics. * Patients with current or past peak panel reactive antibody levels of 25% or greater. * Patients with malignancy or history of malignancy other than successfully treated non-metastatic basal cell or squamous cell carcinoma of the skin. * Patients with any form of substance abuse or psychiatric disorder which, in the opinion of the investigator, might invalidate patient communication with the clinician(s). * Patients who have previously received Simulect.